Voyager Therapeutics to Engage with Investors at Major Events
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a pioneering biotechnology firm, is set to participate in a series of noteworthy investor conferences aimed at promoting its cutting-edge neurogenetic medicines. These events are crucial for industry stakeholders looking to understand the latest advancements in genetic therapy and the company's strategic direction.
Upcoming Conferences and Highlights
Voyager Therapeutics is scheduled to partake in several key events:
- The Truist Securities BioPharma Symposium will be occurring in New York City, featuring an insightful panel on Genetic Medicines at 1:45 p.m. ET.
- During the Guggenheim Inaugural Healthcare Innovation Conference, also in Boston, the company will host a fireside chat at 2:00 p.m. ET.
- The B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit will showcase a virtual fireside chat on the 14th, starting at 1:30 p.m. ET.
- Finally, at the Stifel 2024 Healthcare Conference, Voyager Therapeutics will conduct a fireside chat at 9:45 a.m. ET in New York City.
Webcasts and Event Accessibility
For the conferences marked with an asterisk, comprehensive webcasts will be accessible. Interested parties can find the webcasts on the Investors section of Voyager’s official website, ensuring that those unable to attend in person can still engage with the content. Furthermore, any webcasts will be archived for at least 30 days, allowing for continued access to valuable insights.
Innovative Approaches in Neurology
Voyager Therapeutics is dedicated to harnessing human genetics to find viable treatments for various neurological disorders. Their current pipeline targets significant diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease, alongside others impacting the central nervous system.
Utilizing their innovative TRACER™ AAV capsid discovery platform, Voyager has pioneered the creation of novel capsids and explored their associated receptors. This research aims to enhance brain-targeted delivery of genetic therapies through intravenous means, paving the way for more effective treatment options.
Partnerships and Collaborations
Some programs in Voyager's pipeline are progressing independently, while others are being developed in collaboration with esteemed partners such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, and Sangamo Therapeutics. These partnerships signify a strategic alliance to amplify the reach and impact of their innovative therapies.
Company Contact Information
For press inquiries, Trista Morrison can be reached via email at tmorrison@vygr.com. Investors can connect with Mike Hencke at mhencke@kendallir.com, while media inquiries are encouraged to reach out to Brooke Shenkin at brooke@scientpr.com.
Frequently Asked Questions
What is Voyager Therapeutics known for?
Voyager Therapeutics is known for its advancements in neurogenetic medicines, focusing on treating neurological diseases using innovative genetic therapies.
What major events is Voyager attending?
Voyager is attending conferences such as the Truist Securities BioPharma Symposium, Guggenheim Healthcare Innovation Conference, and Stifel 2024 Healthcare Conference.
Are webcasts available for the conferences?
Yes, webcasts will be available for select conferences and can be accessed via the Investors section of Voyager's website.
What diseases are targeted in Voyager's pipeline?
Voyager's pipeline includes programs for Alzheimer’s, ALS, and Parkinson’s disease, as well as other neurological disorders.
How does Voyager collaborate with other companies?
Voyager collaborates with major companies such as Alexion, Novartis, and AstraZeneca to enhance their research and development efforts.